0.3229

4.69% -0.0159

After Hours: .29 -0.0329 -10.19%

Lunai Bioworks Inc (LNAI)

Overview News Price History Discussions Forecast

Lunai Bioworks Inc stock is traded at $0.3229, with a volume of 27.69M. It is down -4.69% in the last 24 hours and up +75.11% over the past month. Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.

Previous Close:

$0.3388

Open:

$0.3697

24h Volume:

27.69M

Relative Volume:

1.58

Market Cap:

$11.71M

Revenue:

Net Income/Loss:

$-125.52M

P/E Ratio:

-0.0428

EPS:

-7.5468

Net Cash Flow:

$-5.72M

1W Performance:

-9.55%

1M Performance:

+75.11%

6M Performance:

-73.96%

1Y Performance:

+0.00%

1-Day Range:

$0.2621

$0.3697

1-Week Range:

$0.2621

$0.4368

52-Week Range:

$0.1513

$1.66

Lunai Bioworks Inc Stock (LNAI) Company Profile

Name

Lunai Bioworks Inc

Sector

Healthcare (1112)

Industry

Biotechnology (621)

Phone

45 39179840

Address

CENTURY CITY MEDICAL PLAZA, SUITE 906 LOS ANGELES

Employee

Twitter

Next Earnings Date

Latest SEC Filings

LNAI's Discussions on Twitter

Compare LNAI vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LNAI Lunai Bioworks Inc	0.3229	12.29M	0	-125.52M	-5.72M	-7.5468
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Lunai Bioworks Inc Stock (LNAI) Latest News

Apr 15, 2026

Lunai Bioworks signs letter of intent with Geneial for rare disease data collaboration - Investing.com Australia

Apr 15, 2026

What's Behind The Jump In Lunai Bioworks Stock? - MSN

Apr 15, 2026

Lunai Bioworks (NASDAQ: LNAI) and Geneial Sign LOI to Build Rare Disease Patient Cohorts for Pharma Partnerships - PR Newswire

Apr 15, 2026

Lunai Bioworks unit secures defense collaboration for AI chemical threat platform - MSN

Apr 15, 2026

Lunai Bioworks completes $20M transaction to acquire BBB - MSN

Apr 15, 2026

Apr 14, 2026

Reverse split range 1-for-3 to 1-for-30 proposed by Lunai Bioworks (NASDAQ: LNAI) - Stock Titan

Apr 14, 2026

Apr 13, 2026

Lunai Bioworks (LNAI) seeks approval for wide-range reverse stock split to support Nasdaq listing - Stock Titan

Apr 13, 2026

Apr 08, 2026

LNAI Stock Chart | LUNAI BIOWORKS INC (NASDAQ:LNAI) - ChartMill

Apr 08, 2026

Lunai Bioworks (NASDAQ: LNAI) Secures First Revenue-Generating Defense Collaboration Through BioSymetrics, Deploying AI Platform for Chemical Threat Assessment; Additional Engagements Under Discussion - Sahm

Apr 08, 2026

Apr 07, 2026

Lunai Bioworks (LNAI) Stock: New Defence Collaboration Unlocks Revenue and Innovation - parameter.io

Apr 07, 2026

Apr 05, 2026

Lunai Bioworks to acquire CNS drug delivery platform and Alzheimer’s assets for $20M - MSN

Apr 05, 2026

Apr 02, 2026

Lunai Bioworks (NASDAQ: LNAI) asks shareholders to approve up to 1‑for‑30 reverse split - Stock Titan

Apr 02, 2026

Lunai Bioworks Inc (2Q50.MU) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada

Apr 02, 2026

Mar 30, 2026

Lunai Bioworks Inc Com (LNAI) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade

Mar 30, 2026

Lunai Bioworks Expands CNS Portfolio With $20M Acquisition - TipRanks

Mar 30, 2026

Lunai Bioworks Unveils $20M Preferred Investment and Debt-for-Equity Exchange to Advance CNS Assets - TradingView — Track All Markets

Mar 30, 2026

Lunai Bioworks (NASDAQ: LNAI) secures $20M CNS Alzheimer’s deal and converts secured debt - Stock Titan

Mar 30, 2026

Mar 27, 2026

Lunai Bioworks acquires CNS drug delivery tech for $20M By Investing.com - Investing.com Australia

Mar 27, 2026

Mar 26, 2026

Why did LNAI stock skyrocket over 130% pre-market today? - MSN

Mar 26, 2026

Microcap March Madness: LNAI, FAGI, VSA, LNKS Sweet 16 Underdog Watch - Barchart.com

Mar 26, 2026

Lunai Bioworks Acquires $20M in BBB Delivery Tech, CNS Alzheimer’s Assets from Clemann Group - Contract Pharma

Mar 26, 2026

Why did LNAI stock skyrocket over 130% pre-market today? | Tap to know more | Inshorts - Inshorts

Mar 26, 2026